Allopurinol in the prevention of superficial bladder tumour recurrence

Phase 2

Completed

• Conditions: Superficial transitional cell carcinoma of the urinary bladder; Cancer

• Registration Number: ISRCTN65811336
• Lead Sponsor: eicester General Hospital (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08-17
• Last Update Posted: 6 February 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Patients with solitary Transitional Cell Carcinoma
(TCC) Ta or T1 bladder tumour (Grade one to two) that recurs at three months
2. Patients with multifocal TCC Ta bladder tumours (Grade one to two) that do not recur at three months
3. Patients with multifocal TCC Ta bladder tumours (Grade one to two) that recurs at three months

Exclusion Criteria

1. Tumours with a higher risk of progression to muscle-invasive bladder cancer
2. Non-TCC bladder cancer
3. Multifocal T1 or Grade three TCC
4. Carcinoma in situ
5. More than one instillation of intravesical chemotherapy
6. Intravesical Bacillus Calmette-Guerin (BCG) therapy

Other reasons:
1. Current azathioprine or mercaptopurine treatment
2. Serum creatinine more than 200 µmol/l
3. Pregnant
4. Breast feeding
5. Aged under 18 year of age
6. Previous Allopurinol hypersensitivity
7. Current allopurinol treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified